Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × olaparib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 30 Ovarian Neoplasms 8 Breast Neoplasms 8 Pancreatic Neoplasms 7 Urinary Bladder Neoplasms 4 Metastatic Castration-resistant Prostate Cancer 4 Sarcoma 3 Lymphoma, Non-Hodgkin 3 Wilms Tumor 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Neoplasm Metastasis 2 Medulloblastoma 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Glioma 2 Ependymoma 2 Endometrial Neoplasms 2 Central Nervous System Neoplasms 2 Castration-Resistant Prostate Carcinoma 2 Carcinoma, Transitional Cell 2 Carcinoma, Renal Cell 2 Xanthogranuloma, Juvenile 1 Urogenital Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thrombocytosis 1

Interventions

enzalutamide 7 Prednisone 7 cabazitaxel 6 Radiosurgery 6 Docetaxel 5 Androgen Antagonists 4 Abiraterone Acetate 4 XRP6258 2 talazoparib 1 sipuleucel-T 1 rucaparib 1 pembrolizumab 1 olaparib 1 gallium 68 PSMA-11 1 fludrocortisone acetate 1 darolutamide 1 apalutamide 1 Zuclomiphene 1 Standard of Care 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Prednisolone 1 Positron Emission Tomography Computed Tomography 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 LY3023414 1 Injections 1 Hydrocortisone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03434158 2022-11-03

IMANOL

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡